Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

342 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
TAXUS VI 2-year follow-up: randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions.
Grube E, Dawkins KD, Guagliumi G, Banning AP, Zmudka K, Colombo A, Thuesen L, Hauptman K, Marco J, Wijns W, Popma JJ, Buellesfeld L, Koglin J, Russell ME. Grube E, et al. Among authors: thuesen l. Eur Heart J. 2007 Nov;28(21):2578-82. doi: 10.1093/eurheartj/ehm424. Epub 2007 Oct 14. Eur Heart J. 2007. PMID: 17938126 Clinical Trial.
Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice.
Dawkins KD, Grube E, Guagliumi G, Banning AP, Zmudka K, Colombo A, Thuesen L, Hauptman K, Marco J, Wijns W, Popma JJ, Koglin J, Russell ME; TAXUS VI Investigators. Dawkins KD, et al. Among authors: thuesen l. Circulation. 2005 Nov 22;112(21):3306-13. doi: 10.1161/CIRCULATIONAHA.105.552190. Epub 2005 Nov 14. Circulation. 2005. PMID: 16286586 Clinical Trial.
TAXUS VI final 5-year results: a multicentre, randomised trial comparing polymer-based moderate-release paclitaxel-eluting stent with a bare metal stent for treatment of long, complex coronary artery lesions.
Grube E, Dawkins K, Guagliumi G, Banning A, Zmudka K, Colombo A, Thuesen L, Hauptman K, Marco J, Wijns W, Joshi A, Mascioli S. Grube E, et al. Among authors: thuesen l. EuroIntervention. 2009 Mar;4(5):572-7. doi: 10.4244/eijv4i5a97. EuroIntervention. 2009. PMID: 19378676 Clinical Trial.
Five-year long-term clinical follow-up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT FIRST trial.
Wiemer M, Serruys PW, Miquel-Hebert K, Neumann FJ, Piek JJ, Grube E, Haase J, Thuesen L, Hamm C. Wiemer M, et al. Among authors: thuesen l. Catheter Cardiovasc Interv. 2010 Jun 1;75(7):997-1003. doi: 10.1002/ccd.22428. Catheter Cardiovasc Interv. 2010. PMID: 20517959 Clinical Trial.
Six-month results of the NEVO Res-Elution I (NEVO RES-I) trial: a randomized, multicenter comparison of the NEVO sirolimus-eluting coronary stent with the TAXUS Liberté paclitaxel-eluting stent in de novo native coronary artery lesions.
Ormiston JA, Abizaid A, Spertus J, Fajadet J, Mauri L, Schofer J, Verheye S, Dens J, Thuesen L, Dubois C, Hoffmann R, Wijns W, Fitzgerald PJ, Popma JJ, Macours N, Cebrian A, Stoll HP, Rogers C, Spaulding C; NEVO ResElution-I Investigators. Ormiston JA, et al. Among authors: thuesen l. Circ Cardiovasc Interv. 2010 Dec;3(6):556-64. doi: 10.1161/CIRCINTERVENTIONS.110.946426. Epub 2010 Nov 9. Circ Cardiovasc Interv. 2010. PMID: 21062998 Clinical Trial.
Six-month IVUS and two-year clinical outcomes in the EVOLVE FHU trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent.
Meredith IT, Verheye S, Weissman NJ, Barragan P, Scott D, Valdés Chávarri M, West NE, Kelbæk H, Whitbourn R, Walters DL, Kubica J, Thuesen L, Masotti M, Banning A, Sjögren I, Stables RH, Allocco DJ, Dawkins KD. Meredith IT, et al. Among authors: thuesen l. EuroIntervention. 2013 Jul;9(3):308-15. doi: 10.4244/EIJV9I3A52. EuroIntervention. 2013. PMID: 23872647 Free article. Clinical Trial.
The NUGGET study: NIR ultra gold-gilded equivalency trial.
Reifart N, Morice MC, Silber S, Benit E, Hauptmann KE, de Sousa E, Webb J, Kaul U, Chan C, Thuesen L, Guagliumi G, Cobaugh M, Dawkins K; NUGGET Study. Reifart N, et al. Among authors: thuesen l. Catheter Cardiovasc Interv. 2004 May;62(1):18-25. doi: 10.1002/ccd.20026. Catheter Cardiovasc Interv. 2004. PMID: 15103594 Clinical Trial.
Actinomycin-eluting stent for coronary revascularization: a randomized feasibility and safety study: the ACTION trial.
Serruys PW, Ormiston JA, Sianos G, Sousa JE, Grube E, den Heijer P, de Feyter P, Buszman P, Schömig A, Marco J, Polonski L, Thuesen L, Zeiher AM, Bett JH, Suttorp MJ, Glogar HD, Pitney M, Wilkins GT, Whitbourn R, Veldhof S, Miquel K, Johnson R, Coleman L, Virmani R; ACTION investigators. Serruys PW, et al. Among authors: thuesen l. J Am Coll Cardiol. 2004 Oct 6;44(7):1363-7. doi: 10.1016/j.jacc.2004.03.084. J Am Coll Cardiol. 2004. PMID: 15464314 Free article. Clinical Trial.
Coronary bifurcation lesions treated with simple or complex stenting: 5-year survival from patient-level pooled analysis of the Nordic Bifurcation Study and the British Bifurcation Coronary Study.
Behan MW, Holm NR, de Belder AJ, Cockburn J, Erglis A, Curzen NP, Niemelä M, Oldroyd KG, Kervinen K, Kumsars I, Gunnes P, Stables RH, Maeng M, Ravkilde J, Jensen JS, Christiansen EH, Cooter N, Steigen TK, Vikman S, Thuesen L, Lassen JF, Hildick-Smith D. Behan MW, et al. Among authors: thuesen l. Eur Heart J. 2016 Jun 21;37(24):1923-8. doi: 10.1093/eurheartj/ehw170. Epub 2016 May 8. Eur Heart J. 2016. PMID: 27161619 Clinical Trial.
342 results